 |
인쇄하기
취소
|
MFDS approves new treatment for advanced colorectal cancer
Bayer HealthCare Pharmaceuticals on Monday gained the green light from the Ministry of Food and Drug Safety (MFDS) on Stivarga (regorafenib) to treat patients with metastatic colorectal cancer (mCRC).
Stivarga is a multi-kinase inhibitor that blocks several enzymes that promote cancer growth. The conventional chemotherapies for colorectal cancer include fluoropyrimidines, anti-vascular endot...
Stivarga is a multi-kinase inhibitor that blocks several enzymes that promote cancer growth. The conventional chemotherapies for colorectal cancer include fluoropyrimidines, anti-vascular endot...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.